IMPEDE-VTE Score for VTE Risk in Multiple Myeloma
Risk stratification tool for venous thromboembolism (VTE) in patients with multiple myeloma receiving immunomodulatory drug (IMiD) based therapy. Score guides choice of VTE prophylaxis: low risk = aspirin, high risk = anticoagulation (LMWH or DOACs). Developed by Li et al. 2020. Endorsed by IMWG VTE prophylaxis guidelines.
Score interpretation
Low risk of VTE on IMiD-based myeloma therapy
→ VTE prophylaxis with aspirin 75-100 mg daily (or 150 mg daily as per some guidelines); ensure no contraindication to aspirin (peptic ulcer, bleeding history -- if so use PPI cover); counsel patient on signs of DVT/PE; reassess at each cycle or if clinical status changes; document prophylaxis decision in notes.
Intermediate risk; aspirin or LMWH prophylaxis recommended
→ LMWH preferred over aspirin if intermediate risk with additional clinical risk factors (obesity, immobility, infection, dehydration); LMWH: enoxaparin 40 mg OD SC or dalteparin 5000 units OD SC; adjust for renal impairment (creatinine clearance below 30 mL/min: reduce dose or use UFH); alternatively aspirin 150 mg daily if patient declines injection; regular monitoring of anti-Xa levels not routinely required with prophylactic dosing; counsel patient; reassess at each cycle.
High VTE risk; therapeutic or full-dose prophylactic anticoagulation required
→ LMWH prophylactic dose (enoxaparin 40 mg OD SC) or consider therapeutic-dose anticoagulation if active VTE has occurred; alternatively DOAC (rivaroxaban or apixaban) if renal function adequate (creatinine clearance above 30 mL/min) and no significant drug-drug interactions with myeloma regimen; discuss choice with haematologist; duration: continue throughout IMiD therapy; if VTE occurs on prophylaxis -- upgrade to therapeutic anticoagulation (LMWH 1 mg/kg BD or DOAC); thrombophilia screen if first VTE and unexpected; patient education: signs of PE (breathlessness, chest pain, haemoptysis) -- attend ED immediately.
Interpretation bands for the IMPEDE-VTE. Apply clinical judgement and local guidance.
References
- Li A et al. IMPEDE VTE: A novel score that incorporates IMiD-based therapy to predict venous thromboembolism in multiple myeloma. Blood Adv. 2020;4(8):1594-1603.
- Palumbo A et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22(2):414-423.
Related
Curated clinical cross-links plus same-class fallbacks.
- Thalidomide · Immunomodulatory Drug (IMiD) — Myeloma
- Lenalidomide · Immunomodulatory Drug (IMiD)
- Thalidomide (Rheumatology / Dermatology) · Immunomodulatory Drug (IMiD)
- Lenalidomide (Specialist drug) · Immunomodulatory drug (IMiD)
- Pomalidomide (Specialist drug) · Immunomodulator (thalidomide analogue)
- Enoxaparin (LMWH) · Anticoagulant
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.